The earnings call highlighted significant progress in clinical trials, especially in breast and pancreatic cancers, and a solid financial position with new capital access. However, the ongoing search for a new CEO and a decrease in R&D spending present challenges. The overall sentiment is cautiously optimistic with key strategic advancements underway.

Company Guidance -

Q3 2025

During the recent Oncolytics Biotech conference call, several key metrics and strategic updates were shared. The company reported a cash and cash equivalents position of $15.3 million as of March 31, 2025, with a net cash usage of $6.5 million for operating activities in the quarter. Research and development expenses were $4.1 million, a decrease from $5.7 million in the same quarter of the previous year, attributed to lower manufacturing and clinical trial costs. The net loss for the quarter was $6.7 million, equivalent to $0.08 per share. Oncolytics also announced a $20 million share purchase agreement with Alumni Capital, providing additional financial flexibility. Clinically, the company highlighted ongoing trials of pelareorep, particularly in breast and pancreatic cancer, with promising data shared at various medical conferences. The GOBLET Cohort 5 study, supported by a $5 million PanCAN grant, is advancing with more than half of the necessary participants enrolled. The company is also actively advancing its CEO search and exploring multiple business development opportunities.

Progress in Breast Cancer Trials

Two randomized Phase 2 studies showed that pelareorep-based combination therapy substantially outperformed standard care in HR-positive/HER2-negative metastatic breast cancer, with a near doubling of median progression-free survival and two-year survival rate.

Pancreatic Cancer Trial Enrollment

Enrollment for the GOBLET Cohort 5 pancreatic cancer study, funded by a $5 million PanCAN grant, is ongoing with more than half of the Stage 1 patients enrolled.

Financial Runway and Share Purchase Agreement

The company reported $15.3 million in cash and a $20 million share purchase agreement with Alumni Capital, providing financial runway through key milestones and the third quarter of 2025.

Anal Carcinoma Trial Expansion

The GOBLET Cohort 4, investigating pelareorep and atezolizumab in relapsed anal carcinoma, showed a 33% objective response rate, leading to an expansion for Stage 2 enrollment.

Oncolytics Biotech (ONCY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ONCY Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 12, 2025	2025 (Q3)	-0.07 / -	-0.087	―	―	―
Aug 08, 2025	2025 (Q2)	-0.07 / -0.05	-0.073	30.00% (+0.02)	―	―
May 14, 2025	2025 (Q1)	-0.07 / -0.06	-0.065	11.11% (<+0.01)	―
Mar 07, 2025	2024 (Q4)	-0.09 / -0.07	-0.036	-100.00% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.07 / -0.09	-0.102	14.29% (+0.01)	―
Aug 01, 2024	2024 (Q2)	-0.07 / -0.07	-0.087	16.67% (+0.01)	―
May 09, 2024	2024 (Q1)	-0.08 / -0.07	-0.073	10.00% (<+0.01)	―
Mar 07, 2024	2023 (Q4)	-0.11 / -0.04	-0.102	64.29% (+0.07)	―
Nov 03, 2023	2023 (Q3)	-0.08 / -0.10	-0.058	-75.00% (-0.04)	―
Aug 14, 2023	2023 (Q2)	-0.09 / -0.09	-0.065	-33.33% (-0.02)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ONCY Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 14, 2025	$0.52	$0.50	-3.85%
Mar 07, 2025	$0.74	$0.69	-6.76%
Nov 12, 2024	$1.08	$1.12	+3.70%
Aug 01, 2024	$1.03	$1.02	-0.97%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oncolytics Biotech (ONCY) report earnings?

Oncolytics Biotech (ONCY) is schdueled to report earning on Nov 12, 2025, TBA (Confirmed).

What is Oncolytics Biotech (ONCY) earnings time?

Oncolytics Biotech (ONCY) earnings time is at Nov 12, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ONCY EPS forecast?

ONCY EPS forecast for the fiscal quarter 2025 (Q3) is -0.07.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing